Do analysts prefer TH or SVA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sernova 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, BCT or SVA?

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BriaCell Therapeutics N/A N/A N/A -C$0.38 N/A Sernova N/A N/A -C$35.70M -C$0.04 N/A

Is BCT or SVA more profitable?

Sernova's return on equity of 51.72% beat BriaCell Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BriaCell Therapeutics N/A N/A N/A Sernova N/A 51.72% -119.26%

Is SVA or IPA more profitable?

Sernova's return on equity of 51.72% beat ImmunoPrecise Antibodies' return on equity. Company Net Margins Return on Equity Return on Assets Sernova N/A 51.72% -119.26% ImmunoPrecise Antibodies N/A N/A N/A

Which has better valuation and earnings, HBP or SVA?

Helix BioPharma is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Helix BioPharma N/A N/A -C$50.55M -C$0.06 N/A Sernova N/A N/A -C$35.70M -C$0.04 N/A

Is HBP or SVA more profitable?

Sernova's return on equity of 51.72% beat Helix BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Helix BioPharma N/A -36.79% -279.98% Sernova N/A 51.72% -119.26%

Which has better earnings and valuation, SVA or SCYB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sernova N/A N/A -C$35.70M -C$0.04 N/A Scythian Biosciences N/A N/A N/A N/A N/A

Is SVA or SCYB more profitable?

Sernova's return on equity of 51.72% beat Scythian Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sernova N/A 51.72% -119.26% Scythian Biosciences N/A N/A N/A

Sernova (SVA) Competitors

C$0.15 0.00 (0.00%)

As of 06/10/2026 10:12 AM Eastern

Compare

SVA vs. TH, BCT, IPA, HBP, and SCYB

Should you buy Sernova stock or one of its competitors? MarketBeat compares Sernova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sernova include Theratechnologies (TH), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Helix BioPharma (HBP), and Scythian Biosciences (SCYB). These companies are all part of the "biotechnology" industry.

How does Sernova compare to Theratechnologies?

Theratechnologies (TSE:TH) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

0.5% of Theratechnologies shares are owned by institutional investors. Comparatively, 0.0% of Sernova shares are owned by institutional investors. 1.2% of Theratechnologies shares are owned by company insiders. Comparatively, 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Theratechnologies has higher revenue and earnings than Sernova. Theratechnologies is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theratechnologies	C$84.38M	2.44	-C$1.96M	-C$0.19	N/A
Sernova	N/A	N/A	-C$35.70M	-C$0.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theratechnologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sernova	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sernova has a net margin of 0.00% compared to Theratechnologies' net margin of -11.81%. Sernova's return on equity of 51.72% beat Theratechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theratechnologies	-11.81%	16.59%	5.15%
Sernova	N/A	51.72%	-119.26%

In the previous week, Theratechnologies' average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score.

Company	Overall Sentiment
Theratechnologies	Neutral
Sernova	Neutral

Theratechnologies has a beta of 0.256166, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Sernova has a beta of -0.344488, suggesting that its stock price is 134% less volatile than the broader market.

Summary

Theratechnologies beats Sernova on 6 of the 11 factors compared between the two stocks.

How does Sernova compare to BriaCell Therapeutics?

BriaCell Therapeutics (CVE:BCT) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BriaCell Therapeutics	N/A	N/A	N/A	-C$0.38	N/A
Sernova	N/A	N/A	-C$35.70M	-C$0.04	N/A

Sernova's return on equity of 51.72% beat BriaCell Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BriaCell Therapeutics	N/A	N/A	N/A
Sernova	N/A	51.72%	-119.26%

0.0% of Sernova shares are held by institutional investors. 12.1% of Sernova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score.

Company	Overall Sentiment
BriaCell Therapeutics	Neutral
Sernova	Neutral

Summary

Sernova beats BriaCell Therapeutics on 5 of the 6 factors compared between the two stocks.

How does Sernova compare to ImmunoPrecise Antibodies?

Sernova (TSE:SVA) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

ImmunoPrecise Antibodies has higher revenue and earnings than Sernova. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sernova	N/A	N/A	-C$35.70M	-C$0.04	N/A
ImmunoPrecise Antibodies	C$19.47M	8.33	-C$22.19M	-C$0.89	N/A

0.0% of Sernova shares are held by institutional investors. 12.1% of Sernova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sernova's return on equity of 51.72% beat ImmunoPrecise Antibodies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sernova	N/A	51.72%	-119.26%
ImmunoPrecise Antibodies	N/A	N/A	N/A

In the previous week, Sernova's average media sentiment score of 0.00 equaled ImmunoPrecise Antibodies'average media sentiment score.

Company	Overall Sentiment
Sernova	Neutral
ImmunoPrecise Antibodies	Neutral

Summary

Sernova beats ImmunoPrecise Antibodies on 5 of the 8 factors compared between the two stocks.

How does Sernova compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Sernova's return on equity of 51.72% beat Helix BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Helix BioPharma	N/A	-36.79%	-279.98%
Sernova	N/A	51.72%	-119.26%

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.0% of Sernova shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Comparatively, 12.1% of Sernova shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Helix BioPharma has a beta of 0.421776, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Sernova has a beta of -0.344488, meaning that its stock price is 134% less volatile than the broader market.

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score.

Company	Overall Sentiment
Helix BioPharma	Neutral
Sernova	Neutral

Helix BioPharma is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helix BioPharma	N/A	N/A	-C$50.55M	-C$0.06	N/A
Sernova	N/A	N/A	-C$35.70M	-C$0.04	N/A

Summary

Sernova beats Helix BioPharma on 7 of the 8 factors compared between the two stocks.

How does Sernova compare to Scythian Biosciences?

Sernova (TSE:SVA) and Scythian Biosciences (CVE:SCYB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sernova	N/A	N/A	-C$35.70M	-C$0.04	N/A
Scythian Biosciences	N/A	N/A	N/A	N/A	N/A

Sernova's return on equity of 51.72% beat Scythian Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sernova	N/A	51.72%	-119.26%
Scythian Biosciences	N/A	N/A	N/A

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sernova's average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company	Overall Sentiment
Sernova	Neutral
Scythian Biosciences	Neutral

Summary

Sernova beats Scythian Biosciences on 3 of the 4 factors compared between the two stocks.

Get Sernova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sernova	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$52.16M	C$429.91M	C$6.47B	C$11.99B
Dividend Yield	7.86%	3.86%	2.67%	6.20%
P/E Ratio	-3.75	3.18	24.57	36.69
Price / Sales	N/A	6,477.34	479.79	10.03
Price / Cash	6.15	13.13	43.05	82.29
Price / Book	-1.97	83.81	10.27	4.35
Net Income	-C$35.70M	-C$96.07M	C$3.56B	C$299.09M
7 Day Performance	-3.23%	-0.56%	-2.66%	-3.45%
1 Month Performance	-6.25%	1.20%	-0.06%	-2.75%
1 Year Performance	-9.09%	47.66%	20.67%	39.11%

Sernova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sernova	N/A	C$0.15 flat	N/A	-9.1%	C$52.16M	N/A	N/A	1,959	Gap Up
TH Theratechnologies	N/A	C$4.47 -4.9%	N/A	+27.0%	C$205.53M	C$84.38M	N/A	103	Gap Down
BCT BriaCell Therapeutics	N/A	C$10.60 -3.8%	N/A	+0.0%	C$168.68M	N/A	N/A	5
IPA ImmunoPrecise Antibodies	N/A	C$6.50 +0.8%	N/A	+0.0%	C$162.08M	C$19.47M	N/A	80	Gap Down
HBP Helix BioPharma	N/A	C$1.58 +1.3%	N/A	+63.4%	C$120.68M	N/A	N/A	9	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:SVA) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sernova (SVA) Competitors

SVA vs. TH, BCT, IPA, HBP, and SCYB

How does Sernova compare to Theratechnologies?

Summary

How does Sernova compare to BriaCell Therapeutics?

Summary

How does Sernova compare to ImmunoPrecise Antibodies?

Summary

How does Sernova compare to Helix BioPharma?

Summary

How does Sernova compare to Scythian Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sernova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sernova (SVA) Competitors

SVA vs. TH, BCT, IPA, HBP, and SCYB

How does Sernova compare to Theratechnologies?

Do insiders and institutionals believe in TH or SVA?

Which has preferable valuation & earnings, TH or SVA?

Do analysts prefer TH or SVA?

Is TH or SVA more profitable?

Does the media prefer TH or SVA?

Which has more risk & volatility, TH or SVA?

Summary

How does Sernova compare to BriaCell Therapeutics?

Which has better valuation and earnings, BCT or SVA?

Is BCT or SVA more profitable?

Do insiders & institutionals have more ownership in BCT or SVA?

Does the media favor BCT or SVA?

Summary

How does Sernova compare to ImmunoPrecise Antibodies?

Which has higher earnings & valuation, SVA or IPA?

Do insiders & institutionals have more ownership in SVA or IPA?

Is SVA or IPA more profitable?

Does the media refer more to SVA or IPA?

Summary

How does Sernova compare to Helix BioPharma?

Is HBP or SVA more profitable?

Do insiders and institutionals have more ownership in HBP or SVA?

Which has more risk and volatility, HBP or SVA?

Does the media refer more to HBP or SVA?

Which has better valuation and earnings, HBP or SVA?

Summary

How does Sernova compare to Scythian Biosciences?

Which has better earnings and valuation, SVA or SCYB?

Is SVA or SCYB more profitable?

Do insiders and institutionals have more ownership in SVA or SCYB?

Does the media favor SVA or SCYB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sernova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools